Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00068250 · MORE INFO

Limitations, agreements, and source contact

Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma · Source last updated 2018-02-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The 200 mg/m\^2 treatment arm in the phase I component of the study did not open. Outcome measures are categorized as the phase I or phase II study component, but phase I patients at corresponding dose level are included in the phase II analyses.
point Of Contact
email
seiferheldw@nrgoncology.org
organization
NRG Oncology
title
Wendy Seiferheld, M.S.
Complete source fields
certain Agreement
other Details
PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The 200 mg/m\^2 treatment arm in the phase I component of the study did not open. Outcome measures are categorized as the phase I or phase II study component, but phase I patients at corresponding dose level are included in the phase II analyses.
point Of Contact
email
seiferheldw@nrgoncology.org
organization
NRG Oncology
title
Wendy Seiferheld, M.S.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice